MedPath

Candesartan

Generic Name
Candesartan
Brand Names
Atacand, Atacand Hct
Drug Type
Small Molecule
Chemical Formula
C24H20N6O3
CAS Number
139481-59-7
Unique Ingredient Identifier
S8Q36MD2XX

Overview

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Background

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Associated Conditions

  • Hypertension
  • NYHA Functional Class II-IV Heart Failure

Clinical Trials

FDA Approved Products

Candesartan cilexetil
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:8 mg in 1 1
Approved: 2021/10/01
NDC:63629-2127
Candesartan Cilexetil and Hydrochlorothiazide
Manufacturer:ANI Pharmaceuticals, Inc.
Route:ORAL
Strength:16 mg in 1 1
Approved: 2019/10/25
NDC:62559-660
Candesartan Cilexetil and Hydrochlorothiazide
Manufacturer:ANI Pharmaceuticals, Inc.
Route:ORAL
Strength:32 mg in 1 1
Approved: 2019/10/25
NDC:62559-661
CANDESARTAN CILEXETIL
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:16 mg in 1 1
Approved: 2021/09/30
NDC:63629-9842
candesartan cilexetil and hydrochlorothiazide
Manufacturer:Zydus Lifesciences Limited
Route:ORAL
Strength:32 mg in 1 1
Approved: 2022/10/13
NDC:70771-1327

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath